Screening and diagnosis of primary aldosteronism

Cardiovascular Journal of South Africa

Volumn 13, Issue 4, 2002, Pages 166-170

  Rayner, Brian L ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUDROCORTISONE; HYDRALAZINE; METHYLDOPA; POTASSIUM; RENIN; SPIRONOLACTONE; VERAPAMIL;

ADENOMA; ALDOSTERONE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; ENDOCRINE FUNCTION TEST; FLUDROCORTISONE SUPPRESSION TEST; HOSPITALIZATION; HUMAN; HYPERTENSION; MASS SCREENING; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA;

ALDOSTERONE; CRITICAL PATHWAYS; DIAGNOSIS, DIFFERENTIAL; FLUDROCORTISONE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; MASS SCREENING; PREVALENCE; RENIN; SENSITIVITY AND SPECIFICITY;

EID: 0036658586     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Conn JW, Louis LH. Primary aldosteronism, a new clinical entity. Ann Intern Med 1956; 44: 1-15.
2. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence for primary hyperaldosteronism may not be uncommon - twelve percent incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-298.
3. Komiya I, Yamada T, Aizawa T, Takasu N, Niwa A, Maruyama Y, Ogawa A. Inappropriate elevation of the aldosterone/plasma renin activity ratio in hypertensive patients with increases of 11-deoxycorticosterone and 18-hydroxy-11-deoxycorticosterone: a subtype of essential hypertension? Cardiology 1991; 78(2): 99-110.
4. Anderson GH. (Jr), Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4 429 consecutively referred patients. J Hyperten 1994; 12(5): 609-615.
5. Edwards CRW. Disorders of mineralocorticoid secretion. In: Grossman A, ed. Clinical Endocrinolog.y Blackwell Science, 1998; Ch 34: 432-449.
6. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable 'essential' hypertension. JAMA 1965; 193: 100-106.
7. Vallotton MB. Primary aldosteronism. Part I. Diagnosis of primary hyperaldosteronism. Clin Endocrinol 1996; 45(1): 47-52.
8. Rayner BL, Opie LH, Myers JE, Trinder YA, Davidson JS. Screening for primary aldosteronism: normal ranges for aldosterone and renin in three South African population groups. S Afr Med J 2001; 91: 594-599.
9. Rayner BL, Opie LH, Davidson JS. Aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000; 90: 387-394.
10. Gordon RD. Mineralocorticoid hypertension. Lancet 1994; 344: 240-243.
11. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141(12): 1589-1593.
12. Soule SJ, Davidson JS, Rayner BL. The evaluation of primary aldosteronism. S Afr Med J 2000; 90: 387-394.
13. Young WF. Screening and diagnosis of primary aldosteronism (abstract). Primary aldosteronism and adrenal incidentaloma: into the new millennium. Brisbane. 1999: 12.
14. McKenna TJ, Sequiera SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrin Metab 1991; 73: 952-957.
15. Gordon RD, Tunny TJ. Aldosterone-producing adenoma (A-P-A): effect of pregnancy. Clin Exp Hypertens Theory Pract 1982; A4: 1685-1693.
16. Murhpy BF, Whitworth JA, Kincaid-Smith P. Malignant hypertension due to an aldosterone producing adrenal adenoma. Clin Exp Hypertens Theory Pract 1985; A7: 939-950.
17. Bülhler FR, Laragh JH, Baer L, Vaughn ED, Brunner HR, Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972; 287: 1209-1214.
18. Gordon MS, Williams GH, Hollenberg NK. Renal and adrenal responsiveness to angiotensin II: influence of beta adrenergic blockade. Endocrin Res 1992; 18: 115-131.
19. Oparil S. Review of therapeutic modalities acting directly via central pathways. Clin Exp Hypertens 1982; 4: 579-593.
20. Manhem P, Hokfelt B. Prolonged clonidine treatment: catecholamines, renin activity and aldosterone following exercise in hypertensives. Acta Med Scand 1981; 209: 253-260.
21. Gordon RD. Diagnostic investigations in primary aldosteronism. In: Zanchetti A, ed. Clinical Medicine Series on Hypertension. Maidenhead: McGraw-Hill International (UK) Ltd; 2001: 101-114.
22. Cappuccio FP, Markandu ND, Sagnella GA, et al. Effects of amlodipine on urinary sodium excretion, renin-angiotensinaldosterone system, atrial natuiretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991; 5: 115-119.
23. Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ. Effects of nifedipine treatment on renin-angiotensin-aldosterone axis. J Clin Endocrin Metab 1997; 82: 457-460.
24. Brown MJ, Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn's syndrome. Postgrad Med J 1999; 75: 235-236.
25. Lyons DF, Kem DC, Brown RD, et al. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrin Metab 1983; 57: 892-896.
26. Sica DA, Hollenberg NK. The renal profile of eprosartan. Pharmacotherapy 1999; 19: 86S-94S.
27. Guthrie GP (Jr), McAllister RG (Jr), Kotchen TA. Effects of intravenous and oral verapamil upon pressor and adrenal steroidogenic responses in normal man. J Clin Endocrin Metab 1983; 57: 339-343.
28. Leenen FH, Smith DL, Farkas RM, Reeves RA, Marquez-Julio A. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Am J Med 1987; 82: 969-978.
29. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. JRAAS 2001; 2: 156-169.
30. Kem DC, Weinberger MH, Mayes DM, Nugent CA. Saline suppression of plasma aldosterone in hypertension. Arch Int Med 1971; 128: 380-386.
31. Streeten DH, Tomycz N, Anderson GH. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 1979; 67(3): 403-413.
32. Stowasser M. The critical role of adrenal venous sampling (abstract). Primary aldosteronism and adrenal incidentaloma: into the new millennium. Brisbane. 1999: 15.